Key result
Carvedilol at doses of 0.03, 0.1, and 0.3 mg/kg significantly reduced the incidence of lethal ventricular fibrillation to 0%, 0%, and 10%, respectively, compared to 90% in controls (P<.05).
Why the study?
Does carvedilol prevent lethal ventricular fibrillation induced by coronary reperfusion in anesthetized rats?
Does carvedilol prevent lethal ventricular fibrillation induced by coronary reperfusion in anesthetized rats?
Absolute Event Rate: 0% vs 90%
p-value: p=<.05
Carvedilol effectively inhibits reperfusion-induced lethal ventricular fibrillation in an in vivo rat model, likely through combined beta-blocking and antioxidant mechanisms.
No takes yet. Share an insight, caveat, or question.
Carvedilol's anti-VF effect in rats is hypothesis-generating; does not support clinical use pending human trials.
Takusagawa et al. (2000) studied Arrhythmias induced by coronary reperfusion. Carvedilol vs. Control, propranolol, SOD plus catalase, and combination of propranolol and SOD plus catalase was evaluated on Incidence of lethal ventricular fibrillation (VF) (p=<.05). Carvedilol at doses of 0.03, 0.1, and 0.3 mg/kg significantly reduced the incidence of lethal ventricular fibrillation to 0%, 0%, and 10%, respectively, compared to 90% in controls (P<.05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: